Operating Lease, Liability of Inhibikase Therapeutics, Inc. from 30 Sep 2022 to 30 Jun 2025

Taxonomy & unit: us-gaap: USD
Description: Present value of lessee's discounted obligation for lease payments from operating lease.
Summary: Inhibikase Therapeutics, Inc. quarterly Operating Lease, Liability in USD history and change rate from 30 Sep 2022 to 30 Jun 2025.
Inhibikase Therapeutics, Inc. Operating Lease, Liability for the quarter ending 30 Jun 2025 was $37,944, a 79% decline year-over-year.
Source SEC data: View on sec.gov

Operating Lease, Liability, Quarterly (USD)

Operating Lease, Liability, YoY Quarterly Change (%)

Inhibikase Therapeutics, Inc. Quarterly Operating Lease, Liability (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2025	$37,944	-$139,886	-79%	30 Jun 2025	10-Q	14 Aug 2025	2025	Q2
Q1 2025	$74,772	-$134,717	-64%	31 Mar 2025	10-Q	14 May 2025	2025	Q1
Q4 2024	$110,517	-$129,702	-54%	31 Dec 2024	10-K	27 Mar 2025	2024	FY
Q3 2024	$145,210	-$124,833	-46%	30 Sep 2024	10-Q	14 Nov 2024	2024	Q3
Q2 2024	$177,830	-$120,107	-40%	30 Jun 2024	10-Q	14 Aug 2024	2024	Q2
Q1 2024	$209,489	-$115,522	-36%	31 Mar 2024	10-Q	15 May 2024	2024	Q1
Q4 2023	$240,219	-$111,069	-32%	31 Dec 2023	10-K	27 Mar 2024	2023	FY
Q3 2023	$270,043	-$104,025	-28%	30 Sep 2023	10-Q	14 Nov 2023	2023	Q3
Q2 2023	$297,937			30 Jun 2023	10-Q	14 Aug 2023	2023	Q2
Q1 2023	$325,011			31 Mar 2023	10-Q	15 May 2023	2023	Q1
Q4 2022	$351,288			31 Dec 2022	10-K	31 Mar 2023	2022	FY
Q3 2022	$374,068			30 Sep 2022	10-Q	14 Nov 2022	2022	Q3

* An asterisk sign (*) next to the value indicates that the value is likely invalid.